Novocalmin (Metamizole Sodium)

Metamizole sodium, the active ingredient in Novocalmin, is a pyrazolone presented as an unspecified strength/rectal dosage form for rectal use. It delivers analgesic and antipyretic activity, helping to relieve moderate to severe pain and reduce high fever in adult patients requiring rapid symptom control.

GNH USA supplies Novocalmin as a licensed, Good Distribution Practice‑compliant international pharmaceutical supplier, providing the product to hospitals, pharmacies and clinics worldwide under regulated quality standards. Our supply chain ensures traceability and adherence to EU pharmacopeial specifications.

Novocalmin (metamizole sodium) is employed in the management of pain and fever through inhibition of prostaglandin synthesis.

Pain: provides rapid analgesia for moderate to severe acute pain Fever: reduces elevated body temperature in febrile states Post‑operative pain: helps control pain after surgical procedures Cancer‑related pain: may be used as part of multimodal analgesia for cancer patients High‑grade fever: effective in treating high fever unresponsive to other antipyretics

Common Side Effects: - Nausea - Vomiting - Dizziness - Skin rash

Serious or Rare Side Effects: - Agranulocytosis (severe reduction of white blood cells) - Stevens‑Johnson syndrome or toxic epidermal necrolysis - Anaphylactic reaction

Before initiating therapy, consider the following precautions: - Assess renal and hepatic function: evaluate baseline labs to ensure safe use - Monitor complete blood count regularly: detect early signs of agranulocytosis - Avoid use in patients with known hypersensitivity to pyrazolones or related compounds - Use with caution in elderly or debilitated patients: increased risk of hypotension - Do not combine with other myelosuppressive agents: may amplify bone‑marrow toxicity - Store at room temperature: keep in original packaging, protect from moisture and light

Metamizole sodium may interact with several drug classes. Awareness of these interactions helps minimize adverse outcomes.

Major Interactions (Avoid): - Concomitant use with other pyrazolone derivatives: increased risk of severe blood dyscrasias - Co‑administration with bone‑marrow suppressing agents (e.g., chemotherapy): may potentiate agranulocytosis - Combination with anticoagulants (e.g., warfarin): possible enhancement of bleeding risk

Moderate Interactions (Monitor Closely): - NSAIDs: may increase gastrointestinal irritation - ACE inhibitors: can augment hypotensive effects - Diuretics: may affect renal handling and electrolyte balance